“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Third Time’s a Charm? $43M Verdict Overturned Again for Law Firm’s Posts, State Appellate Court Says
“It should go without saying that an integral aspect of
